ZDA
ARQT icon

Zweig-DiMenna Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

Zweig-DiMenna Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-41,500
Closed -$578K – 69
2024
Q4 		$578K Buy
+41,500
New +$455K 0.04% 88

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Zweig-DiMenna Associates's ARQT Position: Q1 2025 in Review

Zweig-DiMenna Associates sold out of Arcutis Biotherapeutics (ARQT) in Q1 2025, closing a stake of 41,500 shares — an estimated $578K sold.

Zweig-DiMenna Associates first reported a position in ARQT in Q4 2024 and held it in 1 quarter. The position peaked at $578K in Q4 2024. 241 funds tracked by Wall St. Rank hold ARQT as of Q1 2025.

  • Zweig-DiMenna Associates reported no remaining Arcutis Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 41,500 Arcutis Biotherapeutics shares in Q1 2025, an estimated $578K.
  • Zweig-DiMenna Associates first reported a position in Arcutis Biotherapeutics in Q4 2024 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Arcutis Biotherapeutics position peaked at $578K in Q4 2024.
  • 241 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2025.

Based on Zweig-DiMenna Associates's 13F filing for Q1 2025, filed 7 May 2025.